Olaparib Induces RPL5/RPL11-Dependent p53 Activation via Nucleolar Stress
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Oncology"
DOI: 10.3389/fonc.2022.821366
Abstract: The poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) Olaparib is a widely used targeted therapy for a variety of solid tumors with homologous recombination deficiency (HRD) caused by mutation of BRCA1/2 or other DNA repair genes.… read more here.
Keywords: rpl5 rpl11; p53 activation; nucleolar stress; p53 ... See more keywords